Bicara Therapeutics Inc. BCAX

Annual Quarterly

No annual revenue total was found in Bicara Therapeutics Inc.'s SEC filings.

Bicara Therapeutics Inc. (BCAX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$107.1 million. As of Jun 30, 2026 it held $497.3 million in cash and investments and $1.2 million in total debt.

Revenue
—
Net income (TTM)
$-185.36M
Operating cash flow (TTM)
$-134.85M
Free cash flow (TTM)
$-135.25M
EPS (TTM)
$-0.00
Dividend per share
None
Shares outstanding
65.47M
+20.1% vs prior year
Net cash
$496.10M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCAX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
2023658

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating income
-$155.6M
-$82.4M
Net income
-$137.9M
-$68.0M
Diluted EPS
-$2.52
-$4.05
Operating cash flow
-$106.8M
-$74.8M
Free cash flow
-$107.1M
-$74.8M
Total assets
$431.0M
$510.0M
Total liabilities
$29.5M
$18.1M
Stockholders' equity
$401.5M
$491.9M
Cash and investments
$414.8M
$489.7M
Total debt
$1.7M
$738,000

Recent SEC filings

Form Description Filed Period
8-K Current report
Material agreement
 Aug 25, 2026 Aug 21, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
 Jul 28, 2026 Jul 23, 2026
8-K Current report
Shareholder vote results
 Jun 10, 2026 Jun 9, 2026
8-K Current report
Other events
 May 21, 2026 May 21, 2026

All 263 Bicara Therapeutics Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.